Join our daily newsletter At The Bell to receive exclusive market insights
- Clarity Pharmaceuticals (CU6) begins treating participants with the highest dosage of Cu SAR-bisPSMA and Cu Sartate to date
- The company is investigating Cu SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC)
- Data from cohort two revealed a reduction in PSA levels greater than 50 per cent in all three participants within weeks of a single dose when using 8GBq
- Meanwhile, cohort three of the neuroblastoma trial showed success at a dose of 275MBq/kg body weight
- CU6 shares are up 3.37 per cent, trading at $1.08 at 1:14 pm AEST
Clarity Pharmaceuticals (CU6) has treated the first patient at the highest dose level of 12GBq in the third cohort of its phase I/II theranostic prostate cancer trial.
This follows positive results in the second cohort, where patients received a smaller dosage at 8GBq.
The trial is investigating treatment options, namely Cu SAR-bisPSMA, for metastatic castrate-resistant prostate cancer (mCRPC).
Data from cohort two showed that SAR-bisPSMA demonstrated a reduction in prostate-specific antigen (PSA) levels greater than 50 per cent in all three participants within weeks of a single dose.
“Results from cohort two are incredibly exciting and we look forward to seeing data from the increased dosing of 12GBq as well as discover the potential positive effects of multidosing on prostate cancer patients,” CU6 Executive Chairperson Dr Alan Taylor said.
Meanwhile, another trial for Neuroblastoma treatment has entered its fourth cohort, using the highest dose of Cu Sartate to date, at 375MBq/kg body weight.
“We hope that the increase in administered activity between cohorts three and cohort four will have a significant impact on radiation-sensitive diseases, such as neuroblastoma, and we look forward to generating the data from the 375MBq/kg body weight dose,” Dr Taylor said.
Prostate cancer is the second most common cancer diagnosed in men and the fifth leading cause of cancer death worldwide, while Neuroblastomas often occur in children younger than five.
CU6 shares were up 3.37 per cent, trading at $1.08 at 1:14 pm AEST.
